ArticleOncology research2025
Real-World Data on Stage III Non-Small Cell Lung Cancer in Vietnam.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with stage III non-small cell lung cancer (NSCLC) present with a heterogeneous disease profile and often require multifaceted treatment strategies. This research aimed to investigate the demographic features, therapeutic patterns, and survival outcomes of such patients in Vietnam. Methods: A retrospective descriptive study was conducted on 731 patients diagnosed with stage III NSCLC American Joint Committee on Cancer (AJCC) 8th edition, at Nghe An Oncology Hospital from January 2018 to August 2024. Descriptive statistics summarized baseline and treatment characteristics. We calculated progression-free survival (PFS) and overall survival (OS) through the Kaplan-Meier approach and compared survival curves with the log-rank test. Prognostic variables were assessed using Cox regression analysis. Results: Patients had a median age of 64 years, and the majority (84%) were male. Disease stages IIIA, IIIB, and IIIC accounted for 26.0%, 49.9%, and 24.1% of cases, respectively. Adenocarcinoma (60.7%) was the most common histological subtype. Initial treatments included surgery (8.5%), concurrent chemoradiotherapy (38.6%), sequential chemoradiotherapy (2.2%), radiotherapy alone (1.4%), systemic therapy (37.3%), and palliative care (12.0%). From 2018 to 2024, the use of systemic therapy declined (88.5% to 21.7%), while concurrent chemoradiotherapy rose significantly (1.1% to 51.5%). Median progression-free survival (mPFS) and median overall survival (mOS) were 8.9 months and 20.5 months, respectively. Patients with stage IIIA had significantly better outcomes (mPFS: 12.6 months; mOS: 32.4 months; Conclusion: For stage III NSCLC, concurrent chemoradiotherapy is still considered the standard treatment, whereas surgery can provide the highest survival advantage in carefully selected cases. Histology, molecular profile, and disease stage are key prognostic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.